Format
Sort by

Send to

Choose Destination

Selected items

Items: 4

1.

Early malignant progression of hereditary medullary thyroid cancer.

Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, Dralle H; European Multiple Endocrine Neoplasia (EUROMEN) Study Group.

N Engl J Med. 2003 Oct 16;349(16):1517-25.

PMID:
14561794
2.

Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.

Chappuis-Flament S, Pasini A, De Vita G, Ségouffin-Cariou C, Fusco A, Attié T, Lenoir GM, Santoro M, Billaud M.

Oncogene. 1998 Dec 3;17(22):2851-61.

3.

Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.

Machens A, Schneyer U, Holzhausen HJ, Raue F, Dralle H.

Surgery. 2004 Nov;136(5):1083-7.

PMID:
15523405
4.

Penetrance and clinical manifestations of non-hotspot germline RET mutation, C630R, in a family with medullary thyroid carcinoma.

Dourisboure RJ, Belli S, Domenichini E, Podestá EJ, Eng C, Solano AR.

Thyroid. 2005 Jul;15(7):668-71.

PMID:
16053382

Supplemental Content

Support Center